R&D revolution could secure good, affordable prices
This article was originally published in Scrip
Companies that want to offer payers a more attractive price to secure market access for their new innovations should try a whole new approach to R&D. Step away from the randomized control trial, consult with patients and exploit data already out there, says Stuart Dollow, chief executive and founder of Vermilion Life Sciences, and you could potentially afford more flexibility on price.
You may also be interested in...
Earlier dialogues would mean faster access to new medicines.
The scheme still includes high rebate rates, but a controversial life cycle adjustment mechanism has been dropped.
The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.